Last reviewed · How we verify
Aristo Sildaristo
Aristo Sildaristo is a phosphodiesterase 5 inhibitor.
Aristo Sildaristo is a phosphodiesterase 5 inhibitor. Used for Erectile dysfunction.
At a glance
| Generic name | Aristo Sildaristo |
|---|---|
| Also known as | Sildenafil |
| Sponsor | Aspargo Labs, Inc |
| Drug class | Phosphodiesterase 5 inhibitor |
| Target | PDE5 |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
Phosphodiesterase 5 inhibitors work by increasing levels of cyclic guanosine monophosphate (cGMP) in the body, leading to smooth muscle relaxation and vasodilation. This can help alleviate symptoms of erectile dysfunction and other conditions.
Approved indications
- Erectile dysfunction
Common side effects
- Headache
- Flushing
- Dizziness
Key clinical trials
- Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject (PHASE1)
- Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aristo Sildaristo CI brief — competitive landscape report
- Aristo Sildaristo updates RSS · CI watch RSS
- Aspargo Labs, Inc portfolio CI